Table 2.
T1 relaxometry, ventricular volumetry, blood flow volumes
| Control n = 44 | BCPC n = 20 | Fontan n = 62 | p value BCPC vs control | p value Fontan vs control | p value Fontan vs BCPC | SLV Fontan. n = 34 | SRV Fontan n = 21 | p value SRV vs SLV | |
|---|---|---|---|---|---|---|---|---|---|
| VEDVi (mL/m2) | 93 ± 13 | 135 ± 30 | 127 ± 41 | < 0.001* | < 0.001* | 0.4* | 119 ± 35 | 144 ± 49 | 0.03 |
| VESVi (mL/m2) | 39 ± 7 | 76 ± 22 | 72 ± 31 | < 0.001* | < 0.001* | 0.5* | 64 ± 22 | 88 ± 40 | 0.05 |
| VSVi (mL/m2) | 54 ± 8.9 | 59.1 ± 14.3 | 55.4 ± 16.3 | 0.2* | 0.6* | 0.3* | 55.7 ± 19.0 | 56.3 ± 12.3 | 0.9 |
| Vmass (g/m2) | 55 ± 12 | 59 ± 15 | 57 ± 9 | 0.3* | 0.5* | 0.4* | 59 ± 10 | 53 ± 10 | 0.02 |
| VEF (%) | 58 ± 5 | 44 ± 7 | 45 ± 8 | < 0.001* | < 0.001* | 0.7* | 47 ± 8 | 40 ± 8 | 0.009 |
| Vmass / VEDV (g/mL) | – | 78 ± 19 | 71 ± 21 | – | – | 0.1 | 70 ± 20 | 76 ± 25 | 0.3 |
| AAO (L/min/m2) | – | 4.2 ± 1.4 | 3.3 ± 0.7 | – | – | 0.01 | 3.2 ± 0.6 | 3.4 ± 0.9 | 0.4 |
| APC (L/min/m2) | – | 1.2 ± 0.7 | 0.7 ± 0.5 | – | – | 0.004 | 0.6 ± 0.4 | 0.7 ± 0.5 | 0.7 |
| Qp/Qs | – | 1.2 ± 0.4 | 1.1 ± 0.2 | – | – | 0.5 | 1.1 ± 0.2 | 1.1 ± 0.1 | 0.5 |
| Hepatic native T1 (ms) | 604 ± 54 | 645 ± 43 | 762 ± 64 | < 0.001* | < 0.001* | 0.04* | 748 ± 51 | 780 ± 78 | 0.07 |
| Hepatic ECV (%) n = 50 (with Gadobuturol) | – | 36.4 ± 4.8 n = 17 | 41.4 ± 4.8 n = 33 | 0.02 | 40.2 ± 4.2 | 43.1 ± 4.7 | 0.1 |
*One way Analysis of variance tested for multiple comparisons with post-hoc Tukey
AAO ascending aortic flow, APC aorto-pulmonary collateral flow, BCPC bidirectional cavopulmonary connection, DAO descending aorta, ECV extracellular volume fraction, Qp pulmonary (venous) blood flow, Qs systemic blood flow, SLV single left ventricle, SRV single right ventricle SVC superior vena cava, VEDVi indexed ventricular end diastolic volume, VEF ventricular ejection fraction, VESVi indexed ventricular end systolic volume, Vmassi indexed ventricular mass, VSVi indexed ventricular stroke volume